Market watch: Upcoming market catalysts in Q4 2013 Nature.com Subsequently, data from the second stage of the trial comparing obinutuzumab head-to-head against rituximab, which were both in combination with chlorambucil, demonstrated a significant improvement on PFS, thus validating results from the first stage ... |